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ABSTRACT
Introduction The importance of patient- reported outcome 
measures (PROMs) for rheumatoid arthritis (RA) clinical 
studies has been recognised for many years. The current 
study aims to describe the RA PROMs used over the past 
20 years, and their performance metrics, to underpin 
appropriate tool selection.
Methods The study included a systematic search for 
PROMs that have been in use over the period 2000–2019, 
with detailed documentation of their psychometric 
properties, and a user- friendly presentation of the 
extensive evidence base.
Results 125 PROMs were identified with psychometric 
evidence available. The domains of pain, fatigue, emotional 
functions, mobility, physical functioning and work 
dominated, with self- efficacy and coping as personal 
factors. Domains such as stiffness and sleep were poorly 
served. The most frequently used PROMs included the 
Health Assessment Questionnaire Disability Index (HAQ), 
the Short Form 36 (SF-36), the EuroQoL and the Modified 
HAQ which, between them, appeared in more than 3500 
papers. Strong psychometric evidence was found for 
the HAQ, and the SF-36 Physical Functioning and Vitality 
(fatigue) domains. Otherwise, all domains except stiffness, 
sleep, education and health utility, had at least one PROM 
with moderate level of psychometric evidence.
Conclusion There is a broad range of PROMs for 
measuring RA outcomes, but the quality of psychometric 
evidence varies widely. This work identifies gaps in key RA 
domains according to the biopsychosocial model.
INTRODUCTION
The impact of rheumatoid arthritis (RA) 
on the health status of the individual has 
long been understood.1–3 With an increased 
understanding of the conceptual basis of 
outcomes in general, the concentration on 
physical aspects associated with early studies 
has expanded to include psychological 
and mental health consequences, and also 
to examine contextual factors which may 
influence the impact of the condition.4–6 As a 
result, an increasing biopsychosocial perspec-
tive is often to be found.7 Thus, for routine 
clinical monitoring, clinical trials, clinical 
epidemiology and other types of health 
services research, a range of outcomes will be 
used. For this work, an ‘outcome’ is defined 
as any indicator (variable) which can be 
used to either describe, or detect change in 
health status, psychological aspects or quality 
of life. Many outcomes used to monitor the 
progression of RA over the past 40 years have 
consisted of patient- reported outcome meas-
ures (PROMs) involving self- completed ques-
tionnaires.1 8 These would focus on symptoms 
such as pain and fatigue, as well as disability 
Key messages
What is already known about this subject?
 ► A wide range of patient- reported outcome measures 
(PROMs) are commonly used for rheumatoid arthritis 
(RA) outcomes.
 ► Some PROMs, for example, Health Assessment 
Questionnaire Disability Index, are well known.
What does this study add?
 ► This is the first comprehensive review of all RA 
PROMs in published studies, including trials.
 ► This work provides a detailed psychometric analysis 
of RA PROMs, and highlights deficits in measure-
ment of several domains.
How might this impact on clinical practice or 
further developments?
 ► Existing PROMs encompass a wide range of do-
mains, and some lesser- known outcomes that may 
be useful for clinicians.
 ► This work enables appropriate selection of PROMs, 
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and quality of life. Most aspects can be catalogued through 
the International Classification of Functioning, Disability 
and Health (ICF) which has been recommended as one 
option for health recording in eHealth Informatics,9 
for example, pain (b280: sensation of pain), mobility 
(d4) or work (eg, d8451—maintaining a job). Quality 
of life is a separate domain consistent with the Wilson 
and Cleary model.4 Together with the environmental 
and personal factors, they constitute the biopsychosocial 
model which defines the individual’s lived experience of 
RA (figure 1).7 10–12
Various systematic reviews have been published to 
help select the most appropriate PROM with the best 
evidence, however, these are frequently associated with a 
single domain or specific joints.13–16 Given the substantial 
number of domains that could be considered, and their 
associated PROMs, a catalogue of available PROMs across 
all relevant domains should be of value. Consequently, 
the current EULAR funded study, aimed to review all 
available PROMs used in RA, together with their perfor-
mance metrics to help make informed choices about the 
most appropriate PROM for a given purpose.
METHODS
The study set out to identify the PROMs that have been 
in use over a 20- year period (2000–2019), and to system-
atically catalogue their psychometric properties. This is a 
sister study of the earlier paper on PROMs used in osteo-
arthritis, using the same methodology which is described 
later.17
Definition of PROM
In this study we define PROM as any patient- (or proxy-) 
completed questionnaire where a set of items are 




Electronic searches were performed in databases indexing 
health- related journals using Medline via PubMed and 
Scopus. Three different searches were used; the first 
to identify PROMs in use during the specified period 
(2000–2019); the second to identify papers for a specific 
PROM where some form of psychometric evidence was 
present; the third to count the number of times a PROM 
was used during the search period. An example of search 
1, as PubMed search criteria, is presented in online 
supplemental file 1. The second search simply adds the 
name of the PROM using ‘AND’ as Boolean operator to 
the first part of the search, but without giving a specified 
period, as the psychometric evidence could arise from any 
period following the construction of the PROM. This was 
to identify the relevant psychometric evidence associated 
with the PROM. The third search removes the psycho-
metric parameters to simply count the use of the PROM 
in RA in PubMed during the period 2000–2019. Targeted 
hand searching of reference lists and other supplemen-
tary sources, such as textbooks, was also performed.
Process of selection and data extraction
Potential papers with a candidate PROM identified in 
search 1 were then screened by two independent reviewers 
(AAK, SK). This included independent screening of the 
titles and abstracts. For search 2, having added the name 
of the PROM to the search criteria without date restric-
tion, papers were included if they met the following 
criteria: (1) the subjects related to the evidence had RA 
and the evidence was RA specific; (2) one or more of the 
Figure 1 The biopsychosocial model of Wilson and Cleary.
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chosen psychometric criteria specific to the PROM (or 
its subscales) in question (eg, reliability) were reported 
in the article; (3) the article was in English and (4) it was 
available in full text. These selected papers were again 
reviewed by two independent reviewers and any disagree-
ments were discussed and resolved with a third reviewer 
(AT).
Reporting
The results are reported in a series of hierarchically 
structured tables and spreadsheets: (i) overall summary 
table—main paper; (ii) PROM- specific summaries—on-
line supplemental file 2; (iii) references for the 
PROMs—online supplemental file 3; (iv) references used 
for evidence—online supplemental file 4 and (v) those 
scales excluded due to lack of evidence—online supple-
mental file 5. The summaries are catalogued according 
to domains such as pain or quality of life, with associated 
ICF classification following, where relevant, in paren-
theses. Those PROMs with subscales will have evidence 
presented at the subscale level and for total scores where 
relevant and, as such, some PROMs will appear more 
than once under subscale- specific evidence and at some 
level of aggregation. Evidence for validity of a subscale is 
accepted at the total PROM level (conditional on it being 
for RA) as this could, for example, be part of a factor 
analysis of domain structures. Reliability must be specific 
to the subscale or aggregate domain, and where several 
studies report, for example, internal consistency relia-
bility (α), the average of those values will be used to deter-
mine the reporting level for reliability. Evidence must be 
condition- specific; so, while a generic PROM may have 
considerable evidence of validity in other conditions or 
in mixed samples, if there is no specific evidence within 
RA, it will be rated as such.
Psychometric evidence
An independent full- text review of each paper identified 
the psychometric evidence. This was collated in accord 
with the domains of the COnsensus- based Standards for 
the selection of health Measurement INstruments check-
list18 (see online supplemental file 4 for the evidence 
papers associated with a given PROM), and summarised 
according to the OMERACT filter of truth (validity), 
discrimination (reliability) and feasibility (see online 
supplemental file 2 for this level of analysis).19 Conse-
quently, evidence is collated which informs on whether 
the PROM is generic- specific or disease- specific, the 
number of items and their response options, its overall 
use and reliability (internal consistency, test–retest relia-
bility, intraclass correlation coefficient and measurement 
error), validity (content, construct, criterion) and feasi-
bility of use.
Discrimination is evaluated by the magnitude of 
internal consistency reliability, and whether or not 
some form of Minimally Important Difference (MID)/
Minimal Clinically Important Difference (MCID) and 
Standardised Response Mean (SRM) is presented. For 
validity, certain PROMs may have been developed orig-
inally, for example, for arthritis in general, and subse-
quently validated for RA, then we designate them as 
a ‘hybrid’ disease- specific PROM (marked D* in the 
PROM- specific summary tables in online supplemental 
file 2). For feasibility, in the current study the focus is on 
how easy it is to understand and how quickly the PROM 
can be completed, as rated by a patient research partner 
educated in research by the Swedish patient organisation. 
This, together with the proprietary status of the PROM 
allows for summarising under the feasibility aspect of the 
OMERACT filter. The summary is presented in a colour 
coded format (figure 2). Consequently, a PROM which 
has more than five separate pieces of evidence of validity, 
has both reliability and responsiveness evidence at the 
highest levels, can be completed in less than 5 min with 
ease, and is free for use in all not- for- profit settings, will 
be rated green on all three OMERACT filter parameters, 
and its summary rating will be green. If on the other 
hand, the PROM was proprietary, then the feasibility 
rating would be yellow, and so would be the summary 
rating, which cannot be higher than the lowest rating of 
any of the three filter categories.
RESULTS
Search 1 identified 7897 abstracts with potential PROMs 
(figure 3). These revealed 1045 PROMs. After excluding 
duplicates, 208 unique instruments satisfying the above 
definition of PROM were remained and put into search 
2. Then 57 of these were excluded in title/abstract 
screening stage and further 26 in full- text screening stage 
due to various reasons. For example, no psychometric 
evidence, specific to RA, was available for 47 of these 
PROMs (online supplemental file 5). Some of them, such 
as the AUSCAN- stiffness with one item only, did not fulfil 
the PROM definition. Some of them were duplicates with 
two separate names (eg, Cochin Hand Function Scale 
and Duruöz Hand Index) therefore decreased to one 
scale in the list.
Eventually, 125 PROMs were identified where psycho-
metric evidence was available. Given the evaluation of 
both subscales and total scores, this led to 263 separate 
assessments of scales/subscales, the overall summary of 
which can be seen in table 1. Most domains represented 
in tables 1–18 in online supplemental file 2 had one or 
more disease- specific PROMs. Some of them were hybrid 
(D*), having been developed in another condition, and 
then revalidated for RA.
A total of 496 papers were reviewed to ascertain the 
psychometric evidence. Some papers had evidence for 
more than one PROM, therefore would appear more 
than once. Pain, fatigue, emotional functions, mobility, 
physical functioning, work and personal factors (eg, self- 
efficacy and coping) dominated the measured domains 
(table 1). The domain, physical functioning, which 
measures two or more of the underlying domains such 
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as self- care and mobility, included 40 scales/subscales 
representing the highest number among all domains.
The majority of (sub)scales in use were disease- specific, 
either originally designed as such, or subsequently vali-
dated for RA. The lack of ‘strong’ evidence for the 
PROMs, would render the classification ‘moderate’ 
(yellow), although this may have been affected by propri-
etary status. There were only two domains, fatigue and 
physical functioning (either alone or composite), that 
had PROMs with strong evidence. Almost all domains 
had a range of PROMs fulfilling ‘moderate’ criteria on 
the OMERACT filter. Likewise, emotional functions 
(eg, depression and anxiety) were also represented with 
a high number of PROMs (n=23), ten of which had 
moderate evidence. The domain ‘work’ was served by 14 
PROMs, three of which with moderate level of evidence. 
In contrast, the domains of stiffness, sleep, education and 
health utility were poorly served with respect to psycho-
metric evidence.
Table 2 shows the most frequently used PROMs, domi-
nated by the Health Assessment Questionnaire Disability 
Index (HAQ), the Short Form 36 (SF-36), the EuroQoL 
and the Modified HAQ which, taken together, appeared 
in more than 3500 papers, with more use during the 
search period than the remaining PROMs taken together. 
Strong psychometric evidence was found for only the 
HAQ, SF-36_Physical Functioning and SF-36_Vitality 
subscales. Those scales listed in table 2 show the domi-
nance of physical functioning in its various guises, with 
only the Hospital Anxiety and Depression Scale (HADS), 
for anxiety and depression, and the Rheumatoid Arthritis 
Quality of Life Scale for needs- based quality of life 
offering a different focus. It is interesting to find Western 
Ontario McMaster Osteoarthritis Index (WOMAC), a 
disease- specific PROM for osteoarthritis, as being one of 
the most used scales in RA. For WOMAC, there are only 
two papers of psychometric evidence showing only weak 
validity evidence for pain and function subscales in RA 
(see online supplemental file 4). Despite this, it has been 
used 57 times during the search period (online supple-
mental file 2) and almost all of these papers are about 
surgery of the knee and hip in patients with RA. This 
finding highlights the fact that WOMAC is commonly 
used in RA for evaluating outcomes of lower extremity 
function after knee and hip surgery.
Domain- specific assessments are presented in tables 
1–18 in online supplemental file 2. Where the domain- 
specific evidence is obtained from a subscale, this is indi-
cated as such within parentheses. Otherwise, the PROM 
is designated ‘Total’ to indicate the evidence arises from 
the total score. In these tables, ‘Use’ represents the 
number of identified studies reporting use of the PROM 
Figure 2 Summary of quality and quantity of reported psychometric evidence of patient- reported outcome measures 
(based on the OMERACT filter). Validity: quantity of evidence (this must be separate papers providing appropriate supportive 
evidence). Discrimination: reliability is a requirement, and reflects the degree of discrimination available. Minimally Important 
Difference (MID)/Minimal Clinically Important Difference (MCID) and Standardised Response Mean (SRM) regarded as best 
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in patients with RA. The PROM- specific references are 
presented in online supplemental file 3, and the papers 
contributing to the detailed psychometric evidence in 
online supplemental file 4, catalogued in the same order 
as the PROM- specific references.
DISCUSSION
In papers published from 2000 to 2019, 125 PROMs 
were found with some psychometric evidence, and these 
were categorised based on the variety of commonly used 
domains. Almost all domains included at least one PROM 
rated as at least ‘moderate’ (yellow) on the OMERACT 
filter summary.
The most dominant domains were those of pain 
(ICF- b280), fatigue (b1300, b4552), emotional func-
tions (b152), physical functioning (d4–d6) either as a 
composite or as its domains, for example, mobility (d4), 
along with work (d8451). This is not surprising as these 
are the common aspects of RA which patients report, and 
include potentially modifying factors relevant for inter-
vention.20–22 Therefore, these domains represent good 
candidates for consideration in various studies along with 
the quality of life, which is also regarded as an important 
domain from a ‘whole person’ perspective.23 24
There are particular issues related to the inclusion of 
PROMs in Randomised Controlled Trials (RCTs), routine 
clinical practice and observational epidemiological 
studies. Regarding the RCTs, it has been argued that the 
selection of PROs for trials depends on the study objective 
as well as the viewpoint of the stakeholder.25 It is further 
argued that there needs to be agreed on prioritisation 
across all stakeholders about what is most important to 
collect in a trial, which is why a prioritisation and selec-
tion process is necessary. For routine clinical practice, 
how and which PROMs should be incorporated into rheu-
matology practice as part of the clinical decision- making 
process is still thought to be controversial.26 Historically 
the HAQ has often been integrated into routine clinical 
monitoring.27 Recently the American College of Rheu-
matology has produced recommendations for Functional 
Assessment Instruments in RA suitable for routine clin-
ical use.28 These include the HAQ- II, Multidimensional 
Health Assessment Questionnaire and the PROMIS Phys-
ical Function Short Form -10 (PROMIS PF SF-10), the 
former two rated yellow in the current study, the latter 
blue. Other PROMs, such as the HADS29 and the Rheu-
matoid Arthritis Work Instability Scale (RA- WIS),30 both 
of which have ‘cut points’ to inform potential referral, 
may offer useful information in a routine clinical setting.
For the future, combining PROs with technology, such 
as computerised adaptive testing, electronic patient- 
reported systems, web- based platforms and patient 
dashboards, could further help PROM integration into 
routine rheumatology clinical practice.26 For observa-
tional studies, the theory underlying the study is critical. 
The Wilson and Cleary model, which incorporates the 
WHO ICF model (although the former published some 
6 years earlier), and extends health status (functioning) 
to include perceived health and perceived quality of life, 
provides the opportunity to examine the factors which 
moderate and/or mediate the relationship between 
health status (symptoms and functioning) and quality 
of life, fully operationalising a biopsychosocial perspec-
tive of the lived experience of those with RA.4 31 For this 
approach, the specification of the focal relationship (eg, 
the primary hypothesis) defines the type of all other third 
variables (eg, mediator, independent contextual vari-
able), and so informs on the data and associated PROMs 
to be collected.32 33
The results from this review provide a domain- specific 
catalogue which can help in consideration of the choice 
of PROMs to be used. PROMs that have either yellow 
or green indicators will be worth considering, condi-
tional on the year of publication. Yellow may indicate a 
propriety status if the feasibility indicator is also yellow, 
and it will be essential to check the status of any PROM to 
ascertain its current propriety status. If necessary, the rele-
vant published papers listed in online supplemental file 
4 can be reviewed and, if required, the detailed psycho-
metric evidence on a PROM- specific spreadsheet can be 
accessed (available from the first author). As new scales 
and psychometric evidence for all scales are emerging 
continuously, a quick search to update (post-2019) the 
existing evidence for any chosen PROM would be wise, 
especially where existing evidence appears weak in the 
current search, and/or the scale is relatively new.
Figure 3 Flow diagram of search results. PROMs, patient- 
reported outcome measures; RA, rheumatoid arthritis.
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The lack of adequate PROMs to evaluate and define 
symptoms such as stiffness and sleep problems, is of 
concern, as both of these are common in RA.34–37 An 
OMERACT initiative is currently underway that hopes 
to address the shortfall in stiffness measurement.38 A 
PROMIS short- form for sleep disturbance (consistent 
with the current study definition of PROM) may offer an 
opportunity, although not yet apparently validated for 
RA.39 Several PROMs measuring personal factors were 
identified, most of which were disease- specific, but there 
was a disappointing level of psychometric evidence asso-
ciated with those PROMs, with only one PROM achieving 
a moderate status. Yet concepts such as self- efficacy, resil-
ience and coping could be hypothesised to play important 
moderating/mediating roles in understanding, for 
example, the impact of health status on the quality of 
life, or between, for example, functional limitations and 
work.11 40 41 In addition, only one simple summated scale 
the Rheumatoid Arthritis Disease Activity Index (RADAI) 
was found for disease activity. This is not surprising as the 
majority of assessments incorporate provider/physician 
input, and therefore would be not included as a PROM 
in the current study.15
This study was one of several EULAR funded initia-
tives to catalogue the available PROMs across several 
rheumatic diseases, leading to the EULAR Outcome 
Measures Library.42 43 There were several limitations to 
the current study. For example, PROMs are usually not 
administered to patients at the subscale level, and so 
the judgement is always based on the full PROM from 
the patient perspective. Only the reliability evidence was 
subscale specific in this study. Validity was usually judged 
by the whole PROM, but sometimes the evidence was 
also available about a related subscale. It is important 
to note that for some scales in RA the total scale and 
its subscales do not have the same psychometric prop-
erties. For example, the World Health Organisation 
Disability Assessment Schedule (WHODAS- II) total is 
blue whereas its subscales have red, also the Bristol Rheu-
matoid Arthritis Fatigue Multidimensional Question-
naire (BRAF- MDQ) and Arthritis Impact Measurement 
Scales have different psychometric properties for their 
subscales and total scores. In addition, no attempt was 
made to judge the quality of the evidence presented, just 
the weight of evidence in support of the PROM in the 
case of truth (validity). Finally, the feasibility was judged 
by just one person with RA.
Some confusion also arose concerning the SF-36. It 
was originally developed by the RAND corporation and 
known as the RAND- Short Form 36 (RAND-36), being 
a short form of much longer survey. It subsequently 
became known as the SF-36, with items identical to the 
RAND-36, but where the scoring of the general health 
and pain scales differed.44 Both are free for use and 
the latter is still in widespread use.45 Subsequently, the 
SF-36 was revised and became the SF-36 V.2.0 which is 
propriety. It has a recall period of both 4 weeks (stan-
dard) and 1 week (acute), rather than just the 4 weeks 
in the earlier version. In the literature, it is quite often 
difficult to ascertain which version of the SF-36 has been 
used. The psychometric summary of the SF-36 makes no 
distinction between versions but is described as though 
it was V.1.0. In this paper, we considered RAND-36 and 
SF-36 as separate PROMs, given that they have separate 
names and scoring systems. As such there was no RA- spe-
cific psychometric evidence attributable to the RAND-36 
with only one evidence paper (see online supplemental 
file 4) and the use count of 20 during the search period.





1 Health Assessment Questionnaire HAQ 71
2 Medical Outcomes Study Short Form 36- Item SF-36 18
3 EuroQol EQ- 5D 121
4 Modified Health Assessment Questionnaire MHAQ 78
5 Routine Assessment of Patient Index Data 3 RAPID3 93
6 Multidimensional Health Assessment Questionnaire MDHAQ 77
7 Hospital Anxiety and Depression Scale HADS 38
8 Disabilities of the Arm, Shoulder and Hand DASH 69
9 Rheumatoid Arthritis Quality of Life Scale RAQoL 120
10 Western Ontario McMaster Osteoarthritis Index WOMAC 20
11 Functional Assessment of Chronic Illness Therapy Fatigue Scale FACIT- F 24
12 Medical Outcomes Study Short Form 6D SF- 6D 125
13 Arthritis Impact Measurement Scales 2 AIMS2 2
14 Medical Outcomes Study Short Form 12- Item SF-12 49
15 Rheumatoid Arthritis Impact of Disease RAID 92
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In conclusion, a significant array of PROMs is available 
to populate RCTs; routine clinical data collection and 
observational studies in RA. The evidence presented here 
provides a domain- specific catalogue of those PROMs 
available until 2019, but readers are encouraged to check 
post-2019 for any new scale or evidence emerging in their 
domain of interest for those PROMs already catalogued. 
Initiatives such as the EULAR Outcome Measures Library 
will further facilitate knowledge about available PROMs, 
and initiatives such as that from OMERACT should facil-
itate the development of new PROMs where shortfalls 
have been shown to exist.
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